rhASM/sorafenib co-treatment reduces tumor volume and shows a trend towards improved survival in mice bearing subcutaneous Huh7 xenografts versus sorafenib alone.

<p>(A) The mean tumor volume of mice treated with rhASM and sorafenib was significantly smaller than that of control mice at day 8 (Dunnett's post-hoc test p = 0.035; ANOVA df (2,30), F = 3.24, p = 0.053). At day 11 both sorafenib (Dunnett's post hoc test p = 0.034) and combined rhASM and sorafenib (Dunnett's post hoc test p<0.001) treated mice had smaller tumors than control mice (ANOVA, df (2,27), F = 12.22, p<0.001). The rhASM/sorafenib combination group also had significantly smaller tumors than the sorafenib group at day 11 (t = 2.32, df (20), p = 0.031). (B) Significantly longer median survival (13 days) of sorafenib treated mice (chi-square 5.02, df (1), p = 0.025) and combined rhASM/sorafenib treated mice (19 days) (chi-square 14.57, df (1), p<0.001) was observed compared to control (11 days). Two mice in the rhASM/sorafenib group lived beyond the 5 week study period, and were eventually sacrificed at day 43 (tumor volume 132 mm³, 267 mm³). *, # p<0.05, ** p<0.001.